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Control of nutrient intake and usage is of paramount importance for cells. This is 
especially true in conditions of high metabolic and anabolic activity seen in rapidly 
dividing cells for example. Cancer cells rewire their metabolic pathways to insure that 
key building blocks required for the synthesis of proteins, amino acids, and lipids are 
generated. A well-known example comes from the Warburg effect where glycolysis is 
stimulated in aerobic conditions to produce, besides ATP, metabolic intermediates 
that will be used for cataplerosis (i.e. synthesis of biomolecules): ribose sugars for 
nucleotides, glycerol and citrate for lipids, and non-essential amino acids for proteins 
[1]. Acetate is another bioenergetics substrate that can be used by cells [2]. It can be 
acquired through diet but can also be derived from ethanol metabolism. Cancer cells 
can use acetate, alongside glucose, as an important carbon source for lipid 
synthesis, in particular under stress conditions such as hypoxia [2]. How the acetate 
conversion to acetyl-CoA, the building block for lipid synthesis, is regulated was 
unknown. Now a study published by Chinese researchers reveals that acetate 
controls its own metabolism by regulating the expression of lipogenic enzymes [3]. 
Exogenous acetate molecules were found on acetylated histones associated with the 
promoters of fatty acid synthase and acetyl-CoA carboxylase α, key enzymes in the 
lipogenesis pathway. Hence, exogenous acetate turns on the expression of genes 
that will promote its conversion to fatty acids. This regulation was mainly occurring in 
hypoxic conditions. It had little impact on the expression of fatty acid synthase and 
acetyl-CoA carboxylase α in normoxic conditions. It is known that in the presence of 
normal levels of oxygen, glucose and glutamine are the main carbon providers for 
acetyl-CoA (>90%) [4]. In these conditions, it may not be necessary to boost the 
cell’s capacity to convert acetate into acetyl-CoA. However, in hypoxic conditions, the 
contribution of glucose and glutamine to acetyl-CoA generation drops dramatically 
and alternative source of carbon are used, acetate in particular [4]. It makes senses 
consequently that it is in conditions of low oxygen that acetate promotes its 
conversion to acetyl-CoA. Acetate therefore controls its own fate in hypoxic cancer 
cells by epigenetic regulation to ensure that following its conversion to acetyl-CoA, it 
efficiently flows through the lipogenic pathway to generate the lipid constituents of 
dividing cells. 
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FURTHER RECOMMENDED READING 
Diabetic retinopathy is a frequent microvascular complication and one of today’s 
major causes of blindness [1]. Epidemiological studies have shown that plasma LDL 
cholesterol levels were not associated with the incidence of retinopathy but with its 
severity [2;3]. Yu and collaborators present novel evidence for the role of LDL in 
diabetic retinopathy progression [4]. Injecting human preparations of LDL in the 
vitreous humour, they observed that oxidized glycated LDL, but not normal LDL, 
induced inflammation with progressive disruption of retinal layers in diabetic mice but 
not in non-diabetic mice. Thus, the cytotoxic effect of lipoproteins seems to be linked 
with the extravasation into the retinal tissue and their modification by glycation and 
oxidation. This was accompanied with an increased retinal vascular permeability 
resembling clinical diabetic retinopathy. In addition of retinal inflammation and 
injuries to retinal vessels, oxidized glycated LDL induced alterations to retinal 
architecture, impaired function, ER stress and propensity to apoptosis. This data 
supports the concept that lipoproteins have important consequences in diabetic 
retinopathy when extravasated and modified. This is of importance in the quest of 
therapeutic strategies to ameliorate prognosis of diabetic retinopathy and thus 
preserve vision.   
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